You are here: Industry Insights > Market News > Dr. Reddy's Laboratories Announces the Launch of Venlafaxine ER Tablets in the U.S. Market

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

Hot Products

Propantheline Bromide

carbomer 974P

Coenzyme Q10

Refined Fish Oil

Black Currant Extract

Hydrocortisone

Dr. Reddy's Laboratories Announces the Launch of Venlafaxine ER Tablets in the U.S. Market

AmericanPharmaceuticalReviewDecember 13, 2021

Tag: Venlafaxine , USFDA , Dr. Reddy

Favorites

Dr. Reddy’s Laboratories Ltd. announced the launch of Venlafaxine ER Tablets which is therapeutically equivalent to Venlafaxine Extended-Release Tablets, 150 mg and 225 mg, of Osmotica Pharmaceutical US LLC approved by the U.S. Food and Drug Administration (USFDA).

The brand and generic had U.S. sales of approximately $51 million MAT for the most recent twelve months ending in October 2021 according to IQVIA Health*.

Dr. Reddy’s Venlafaxine ER Tablets are available in 150 mg and 225 mg strengths in bottle count sizes of 30 and 90.

Previous:EMA recommends RoActemra in adults with severe COVID-19

Next:Lilly and Regor sign deal to develop treatments for metabolic disorders

Sartorius to Advance Drug Discovery and Manufacturing with AI in Collaboration with NVIDIA

Biotech NewswireMay 17, 2024

The expanded collaboration includes increasing adoption of the NVIDIA Clara suite of AI-powered computing platforms, software, and services in the Sartorius ecosystem.

InnoCare Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis

PharmaSourcesMay 16, 2024

Sartorius Collaborates with Sanofi to Commercialize End-To-End Platform for Downstream Process Intensification

Biotech NewswireMay 14, 2024

Dr. Reddy's Laboratories Announces the Launch of Venlafaxine ER Tablets in the U.S. Market | Pharmasources.com

Touchlight Genetics and the National Physical Laboratory (NPL) Awarded Grant to Develop Novel Gene-Length Single-Stranded Genome Editing Template

Biotech NewswireMay 10, 2024

Nucleic Acid Medicines Manufacture, Round 2 call.

Dr. Reddy's Laboratories Announces the Launch of Venlafaxine ER Tablets in the U.S. Market

Related News

Sartorius to Advance Drug Discovery and Manufacturing with AI in Collaboration with NVIDIA

InnoCare Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis

Sartorius Collaborates with Sanofi to Commercialize End-To-End Platform for Downstream Process Intensification

Touchlight Genetics and the National Physical Laboratory (NPL) Awarded Grant to Develop Novel Gene-Length Single-Stranded Genome Editing Template

You may like